Company profile
Orthox Limited is a UK company with status active founded in 2008 based in South East England.
Updated 06 Jun 2026 16:52
Financial period: 1 Mar 2024 to 28 Feb 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
CH01 | Transaction MzQ0MDcwMzMyMGFkaXF6a2N4
Published 23 Oct 2024 04:39
AA | Transaction MzQzMjY0MjQ0NWFkaXF6a2N4 | Paper/PDF filed
Published 26 Aug 2024 06:37
Company registered at Companies House
1 May 2026 to 31 Jan 2027
Our project aims to create a new type of medical implant that can help people with serious damage to the cartilage and bone in their knee. These injuries often lead to arthritis, pain, difficulty walking, and eventually major surgery such as a total knee replacement. Many people - especially younger adults - have few good treatment options today. Current ...
1 Feb 2020 to 30 Apr 2021
Osteoarthritis is a crippling disease caused by damage to cartilage and the underlying bone in the body's joints. Arthritis Research UK have estimated that osteoarthritis will cost the NHS £118.2bn between 2017 and 2027\. The only widely accepted treatment for osteoarthritis is replacement of the joint with a large, permanent implant. This requires major ...
1 Jun 2015 to 28 Feb 2019
This project will further develop an implant to restore mobility and prevent deterioration of the knee joint in patients suffering from injuries to the meniscal cartilage in their knees. The implant is made from a novel material called FibroFix which is formed from a protein extracted from silk fibres called fibroin. The properties of fibroin give FibroFi...
1 Jan 2014 to 30 Sep 2017
This project will develop an implant to reduce pain and restore mobility to patients suffering from injuries to the cartilage in their knees. The implant is made from a novel material called FibroFix™ which is formed from a protein extracted from silk fibres called fibroin. The properties of fibroin give FibroFix™ devices unique advantages, allowing them ...
1 Feb 2013 to 30 Apr 2015
Cartilage acts as a shock absorber and an articulating surface in human joints. Cartilage defects often progress to severe osteoarthritis (OA), and eventually, total joint replacement is frequently required. The project will develop FibroFix Composite, an extremely tough new biomaterial and will deliver this in anatomically congruent, high strength, tissu...
1 Sep 2011 to 30 Apr 2013
The meniscus has a poor blood supply and as a result ~90% of injuries do not heal. In the majority of these cases, surgery is required to remove the damaged tissue which if left untreated causes significant discomfort and impairs mobility (1). The surgical procedure, a partial meniscectomy, alleviates the symptoms but destabilises the knee joint, resultin...
1 May 2011 to 31 Jul 2011
Awaiting Public Summary
1 Jul 2010 to 31 Mar 2011
Awaiting Public Summary
1 Jul 2010 to 31 Mar 2011
Awaiting Public Summary
